SCN8A and Alzheimer disease: However, increased expression and activity of Nav1.6 in early AD provides the opportunity for increased potency in diseased tissues, and functional studies illustrate the potential of Nav1.6 as a therapeutic target for the correction of aberrant hyperexcitability.